Strategies for Enhancing the Accumulation and Retention of Extracellular Matrix in Tissue-Engineered Cartilage Cultured in Bioreactors by Shahin, Kifah & Doran, Pauline M.
Strategies for Enhancing the Accumulation and
Retention of Extracellular Matrix in Tissue-Engineered
Cartilage Cultured in Bioreactors
Kifah Shahin
1, Pauline M. Doran
2*
1School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, New South Wales, Australia, 2Department of Chemical Engineering, School
of Biological Sciences, Monash University, Melbourne, Victoria, Australia
Abstract
Production of tissue-engineered cartilage involves the synthesis and accumulation of key constituents such as
glycosaminoglycan (GAG) and collagen type II to form insoluble extracellular matrix (ECM). During cartilage culture,
macromolecular components are released from nascent tissues into the medium, representing a significant waste of
biosynthetic resources. This work was aimed at developing strategies for improving ECM retention in cartilage constructs
and thus the quality of engineered tissues produced in bioreactors. Human chondrocytes seeded into polyglycolic acid
(PGA) scaffolds were cultured in perfusion bioreactors for up to 5 weeks. Analysis of the size and integrity of proteoglycans
in the constructs and medium showed that full-sized aggrecan was being stripped from the tissues without proteolytic
degradation. Application of low (0.075 mL min
21) and gradually increasing (0.075–0.2 mL min
21) medium flow rates in the
bioreactor resulted in the generation of larger constructs, a 4.0–4.4-fold increase in the percentage of GAG retained in the
ECM, and a 4.8–5.2-fold increase in GAG concentration in the tissues compared with operation at 0.2 mL min
21. GAG
retention was also improved by pre-culturing seeded scaffolds in flasks for 5 days prior to bioreactor culture. In contrast,
GAG retention in PGA scaffolds infused with alginate hydrogel did not vary significantly with medium flow rate or pre-
culture treatment. This work demonstrates that substantial improvements in cartilage quality can be achieved using scaffold
and bioreactor culture strategies that specifically target and improve ECM retention.
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Introduction
Millions of people in all age groups suffer the debilitating effects
of injury or disease of articular cartilage with incidence increasing
in the elderly. Cartilage damage is commonly initiated by trauma,
autoimmune disease, or osteoarthritis and may develop into a
condition of irreversible deterioration. Tissue engineering of
cartilage is a cell-based approach for the treatment of joints
affected by irreparable cartilage damage [1], offering the potential
for better clinical outcomes than can be achieved using current
surgical practices and prostheses.
The quality of cartilage produced in vitro using tissue engineering
techniques is determined by many parameters including cell
source, cell expansion method, choice of scaffold for cell
attachment, seeding technique, culture environment, nutrients,
differentiation factors, and mechanical stimulation. Porous three-
dimensional scaffolds are an integral component, distinguishing
tissue engineering from standard cell culture techniques. The
scaffold provides physical cues to the attached cells and can mimic
extracellular matrix (ECM) in guiding cell differentiation while
allowing nutrient and waste exchange with the environment.
Poly(a-hydroxy ester)s such as polyglycolic acid (PGA), polylactic
acid, and their co-polymers are of particular interest as scaffold
materials because they are biodegradable, approved for surgical
use, and widely used clinically in humans.
Culture of seeded scaffolds in a dynamic environment involving
fluid flow or mixing is beneficial for cartilage synthesis compared
with static culture conditions [2–5]. Various bioreactor devices
have been applied for cartilage tissue engineering [6,7], offering
advantages such as better control over culture conditions, reduced
diffusional limitations for delivery of nutrients and metabolites,
enhanced oxygen transfer and gas exchange, and exertion of
mechanical and hydrodynamic forces influencing cell and tissue
development. Bioreactor cultivation periods used for cartilage
production range from days to months. Direct perfusion or
recirculation bioreactors, which have a relatively simple configu-
ration and are designed to force a recirculating flow of culture
medium through porous cell-seeded scaffolds, have been shown in
several studies to improve cartilage ECM production compared
with static culture systems [8–10].
Theoretical studies have been used to calculate the medium flow
rates required in bioreactors to deliver adequate oxygen and
nutrients in cartilage cultures [11,12] and to exert flow-induced
shear stresses suitable for mechanical signal transduction in the cells
[13]. Yet, flow of medium through nascent constructs has the
potential to strip ECM components such as glycosaminoglycan
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formation. Loss of ECM into the medium after synthesis represents
a substantial waste of resources and cellular activity in cartilage
cultures. The quantity of material released reflects to some extent
the porosity and structural properties of the scaffold and developing
matrix butis alsoaffected by the hydrodynamic and other operating
conditions applied during bioreactor culture [3,10,14].
Typically, the concentration of collagen achieved in tissue-
engineered cartilage is substantially lower than that in native
articular cartilage [2,5,15–17]. Because networks of collagen type II
fibrils are responsible for the tensile strength of cartilage, tissue-
engineered constructs generally exhibit inferior mechanical prop-
erties compared with native articular cartilage [18,19]. Collagen
networks also play an important role in the retention of
macromolecules within developing tissues: for example, collagen is
necessary for the retention of newly synthesized proteoglycans to
form insoluble cartilage matrix [20]. Collagen in tissue-engineered
cartilage may not be fully assembled into thick collagen fibrils
[21,22]: as in fetal cartilage, it is likely that the C- and/or N-
terminal propeptides of extracellular procollagen molecules remain
in place, thus preventing final aggregation into the banded fibrils
characteristic of mature cartilage [23,24]. Under these conditions,
GAG retention in the tissues may be compromised by the relatively
loose structure of the prevailing procollagen network. On the other
hand, in the same way that proteolysis and turnover of
proteoglycans occur routinely in cartilage in vivo [25], it is also
possible that GAG is lost from cartilage constructs as a consequence
ofproteoglycandegradationandtheformationoffragmentsthatare
easily removed from the tissues, especially under flow conditions.
In previous work in this laboratory, recirculation perfusion
bioreactors were developed for cartilage tissue engineering using
PGA scaffolds [16]. However, loss of up to 72% of ECM
components from the constructs into the medium was identified as
a significant problem reducing the overall quality of the tissues
generated. The aim of the current work was to establish new
culture protocols to address this issue and minimize ECM losses
during bioreactor operation. Several approaches were taken.
PGA–alginate scaffolds were tested to determine whether the
presence of hydrogel within the interstices of fibrous PGA mesh
could improve ECM retention compared with PGA alone.
Different bioreactor operating conditions including high, low,
and gradually increasing flow rate regimes were evaluated for their
effect on ECM loss and cartilage composition. In addition, as a
protective strategy to improve subsequent tissue retention, scaffold
pre-culture was used prior to perfusion culture to allow some
cartilage matrix to be deposited within the scaffolds before
imposition of medium flow. New information about the mecha-
nism of GAG loss from the constructs was obtained by analyzing
the integrity of proteoglycan complexes recovered from the culture
medium to identify whether proteolytic processing affected GAG
retention. Human chondrocytes were employed in this work as a
more pertinent system for clinical applications than animal
models. Human fetal cartilage cells, although not fully differen-
tiated into mature chondrocytes, have been shown previously to
possess a greater capacity for cartilage synthesis than human
mesenchymal stem cells [26] and have the advantage of faster
growth rate, greater developmental plasticity, and thus easier
manipulation compared with adult chondrocytes.
Materials and Methods
Cells, scaffolds and seeding
This research was conducted with approval from the University
of New South Wales Human Research Ethics Committee.
Chondrocytes were isolated from human fetal epiphyseal cartilage
in knee and hip joints obtained with written informed parental
consent after 16–20 weeks of gestation. The cells were expanded
over two passages (P2) in monolayer as described previously [17].
The scaffolds were disks of fibrous PGA mesh of bulk density
58 mg cm
23, porosity 94%, and fiber diameter 12–15 mm (Albany
International Research, Mansfield, USA). The disk diameter was
15 mm and the disk thickness was 4.6 mm.
The scaffolds were seeded using semi-static and PGA–alginate
loading methods [17] and 20610
6 P2 cells. Briefly, for semi-static
seeding, suspended cells were loaded into PGA disks in well plates
using a pipette, the scaffolds were turned over manually for the
first 2.5 h to encourage uniform distribution of cells within the
disks, and incubation was carried out for 3 days in shaking T-flasks
positioned at an angle of about 30u above horizontal on a rotary
shaker operated at 65 rpm. For PGA–alginate seeding, cells
suspended in a solution containing 1.2% sodium alginate were
loaded into PGA disks using a pipette. The scaffolds were treated
with CaCl2 to gelify the alginate, transferred to shaking T-flasks,
and incubated for 3 days as described for semi-static seeding. After
seeding, there was no significant difference in cell density between
the PGA and PGA–alginate scaffolds [17].
Bioreactor cultures
Seeded scaffolds were cultured at 37uC in triplicate custom-built
recirculation column bioreactors [16] in a 5% CO2 incubator.
Each bioreactor was operated using 200 mL of complete medium
[17]. The culture conditions tested are summarized in Table 1.
Scaffolds in the bioreactors were perfused with medium using
three different flow rate regimes. Constant volumetric flow rates of
0.2 mL min
21 (high flow rate) and 0.075 mL min
21 (low flow
rate) were used, corresponding to superficial linear velocities
(=volumetric flow rate/reactor cross-sectional area) of 19 mms
21
and 7 mms
21, respectively. In other experiments, a gradual
increase in flow rate was applied, starting from 0.075 mL min
21
at the beginning of the culture and increasing by about
0.025 mL min
21 each week and twice in the last week to give a
final flow rate of 0.2 mL min
21. Some seeded scaffolds were pre-
cultured in 150-cm
2 shaking T-flasks containing 200 mL of
complete medium and one construct per flask for either 5 days
or 2.5 weeks prior to bioreactor culture at a constant medium flow
rate of 0.2 mL min
21 (Table 1). Non-perfused control cultures
were also carried out for 5 weeks in shaking T-flasks. During all
bioreactor and T-flask cultures and pre-cultures, 100 mL of spent
medium was removed and replaced with fresh medium every 3
days or twice per week. In the bioreactors, the flow direction was
reversed each time the medium was exchanged: irrespective of the
direction of liquid flow through the scaffolds, medium always
flowed against gravity as the bioreactor chambers were inverted
after each change in flow direction. All bioreactor and T-flask
experiments were conducted in triplicate.
Cartilage constructs were harvested after a total cultivation time
after seeding of 5 weeks. The harvested scaffolds were washed,
weighed, and sectioned for biochemical and histological assays as
described previously [17]. Samples of spent culture medium were
stored at 220uC for analysis.
Biochemical and histological analyses
Tissue-engineered cartilage was analyzed for wet weight, dry
weight, water content, and cell, GAG, total collagen, and collagen
type II concentrations as described previously [17]. GAG and
hydroxyproline concentrations were also measured in medium
samples. For correct estimation of GAG release into the medium,
GAG was determined to be stable in the medium for at least 2
ECM Synthesis and Retention in Engineered Cartilage
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Alginate residue in cartilage tissues produced using PGA–alginate
scaffolds was measured by weighing small tissue sections before
and after incubation in alginate-dissolving buffer containing
0.15 M NaCl and 55 mM tri-sodium citrate with gentle shaking
for 10 min at 37uC.
Samples were prepared for histological analysis as described
previously [17]. Tissue sections were immunostained with
monoclonal antibodies against collagen type I (clone I-8H5: ICN
Biomedicals, Seven Hills, Australia) and collagen type II (clone II-
4C11: ICN Biomedicals) using a Bond automated immunostainer
and Bond Polymer Refine Detection Kit (Leica Microsystems,
North Ryde, Australia). The kit contained hydrogen peroxide to
block endogenous peroxidase, serum for protein blocking,
secondary immunoglobulins, polymer tertiary solution, diamino-
benzidine chromogen, and haematoxylin counterstain. The
primary antibodies were used at dilutions of 1:20,000 for collagen
type I and 1:2000 for collagen type II and the incubation time was
30 min. Before immunostaining, the hydrated tissue sections were
treated for 30 min at 37uC with 0.2% hyaluronidase (testicular
type III: Sigma, St Louis, USA) in Tris-buffered saline (TBS:
prepared as a 106solution using 1 M Tris base, 2 M NaCl, and
50 mM CaCl2 in Milli-Q water, pH 8.0) to remove proteoglycans,
and then treated with an antigen retrieval solution (Novacas-
tral
TM: Leica Microsystems) for 20 min at 95uC, washing with
TBS after each step.
Proteoglycan extraction and analysis
Proteoglycans were isolated from tissue-engineered constructs
and human fetal cartilage using the guanidine extraction method
[27]. The extract was cleared by centrifugation, dialyzed for 48 h
using multiple changes of distilled water at 4uC, and then freeze-
dried. To prevent interaction between highly charged proteogly-
cans and other molecules in the spent medium, guanidine-HCl
was added at a concentration of 4 M [28]. The medium was
dialyzed against water and then freeze-dried.
A composite gel containing 1.2% acrylamide and 0.6% agarose
was prepared for electrophoresis of intact proteoglycans [29–31].
The gel was cast into 8 cm68c m 61.5 mm slabs. Freeze-dried
samples were reconstituted in sample buffer [31] to give a
concentration of 0.25 mg mL
21 GAG, heated for 5 min in boiling
water, and loaded on to the gel using a volume of 10 mL. Two gels
containing the same samples were run in parallel. Using 0.04 M
cold Tris-acetate as electrode buffer, the gels were pre-run for 1 h
at 120 V to remove unpolymerized acrylamide [31]. The
electrode buffer was then changed and the samples were loaded
and separated in the cold for 2 h using a current of 28 mA per gel.
The potential difference between the upper and lower buffer
compartments was around 90 V. Bovine aggrecan (Sigma) and
shark chondroitin sulphate (Sigma) were used as size markers. To
evaluate the effectiveness of separation, bovine aggrecan was
mixed 1:1 w/w with chondroitin sulphate or 1:1 w/w with
proteoglycan isolated from fetal cartilage. Proteoglycans in the
culture medium formed aggregates and did not separate well on
the gel. To dissociate the aggregates, the sample concentration was
reduced to 0.08 mg mL
21 GAG by diluting with freshly made 6 M
urea in 0.04 M Tris-acetate. Alternatively, samples were treated
with 0.2% hyaluronidase in 0.04 M Tris-acetate for 30 min at
37uC before boiling and loading on to the gel.
After electrophoresis, the gels were fixed for 60 min using 50%
methanol and 10% acetic acid in Milli-Q water, stained for at least
2 h with a solution of 0.025% toluidine blue in 3% acetic acid,
destained for 2–3 h using 3% acetic acid in multiple changes, and
then cleared overnight in water. Transblotting on nitrocellulose
(pore size 0.45 mm: Invitrogen, Carlsbad, CA, USA) was carried
out in the cold for 1.5 h at 100 V using a transfer buffer
containing 5% methanol [31]. Two nitrocellulose membranes
were placed one on top of the other against the gel to avoid the loss
of small-size molecules during the transfer; the second membrane
acted as a back-up to bind any proteins that might pass through
the first membrane. The blotted membranes were immunode-
tected using monoclonal antibody against human aggrecan
targeted specifically to the hyaluronic-acid-binding region of the
aggrecan molecule (clone 969D4D11: Invitrogen). A Wester-
nBreeze
TM Chemiluminescent Detection kit (anti-mouse: Invitro-
gen) was used according to the manufacturer’s instructions to
detect bound primary antibodies. Visible chemiluminescence was
imprinted and then developed on X-ray film.
Statistical analysis
All culture experiments were performed in triplicate. Data are
presented as averages 6 standard errors. The Student’s t-test was
used to compare two groups of data; one-way analysis of variance
(ANOVA) in conjunction with Fisher’s Protected Least Significant
Difference (PLSD) and Tukey–Kramer multiple-comparisons tests
were used to compare three or more groups of data. When both
Table 1. Scaffolds and culture conditions tested.
Experiment Scaffold T-flask culture period Bioreactor culture period
Bioreactor medium flow rate
(mL min
21)
1 PGA 5 weeks NA NA
2 PGA 0 5 weeks 0.2 (high)
3 PGA 0 5 weeks 0.075 (low)
4 PGA 0 5 weeks 0.075–0.2 (gradually increasing)
5 PGA 5 days 30 days 0.2 (high)
6 PGA 2.5 weeks 2.5 weeks 0.2 (high)
7 PGA–alginate 0 5 weeks 0.2 (high)
8 PGA–alginate 0 5 weeks 0.075–0.2 (gradually increasing)
9 PGA–alginate 5 days 30 days 0.2 (high)
NA=not applicable.
All cultures were conducted using triplicate T-flasks and/or bioreactors.
doi:10.1371/journal.pone.0023119.t001
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level, the p value of the Fisher’s PLSD test is reported.
Results
Effect of bioreactor hydrodynamics and scaffold pre-
culture using PGA scaffolds
Experiments were conducted with the aim of limiting the loss of
ECM components from constructs into the medium during
bioreactor culture. Two approaches were tested using PGA
scaffolds. Low (0.075 mL min
21) and gradually increasing
(0.075–0.2 mL min
21) medium flow rates were applied to
determine if moderation of the hydrodynamic forces within the
perfused scaffolds improved GAG retention compared with
operation at 0.2 mL min
21 as used previously [16]. Pre-culture
of scaffolds for 5 days or 2.5 weeks in T-flasks without perfusion
was also examined to assess whether deposition of cartilage matrix
prior to bioreactor culture could play a protective role in
minimizing subsequent ECM losses under perfusion conditions.
Results from Experiments 1–6 (Table 1) for PGA scaffolds are
shown in Figures 1 and 2. Relatively low construct wet weights
were obtained for the non-perfused, high flow rate, and 2.5-week
pre-culture groups (Fig. 1a). The construct wet weights formed
using low and gradually increasing flow rates were 4.8-fold
(p,0.0001) and 5.7-fold (p,0.0001) higher, respectively, than
those in the high flow rate cultures. Pre-culture of scaffolds for 5
days prior to bioreactor culture also improved the construct wet
weight 5.3-fold (p,0.0001) relative to high flow rate operation.
These results are consistent with visual observations of construct
shrinkage in the non-perfused, high flow rate, and 2.5-week pre-
culture experiments after Days 20–25 of the 5-week culture period:
construct shrinkage did not occur when low and gradually
increasing medium flow rates were used or when the scaffolds
were pre-cultured for 5 days. The water contents of the constructs
were (86.460.7)%, (86.361.6)%, (91.460.0)%, (89.660.3)%,
(88.761.2)%, and (85.960.6)% for the non-perfused control, high
flow rate, low flow rate, gradual increase in flow rate, 5-day pre-
culture, and 2.5-week pre-culture groups, respectively. The
numbers of cells in constructs harvested from the high flow rate,
low flow rate, and 2.5-week pre-culture experiments were not
significantly different from those in the non-perfused controls
(Fig. 1b). In contrast, cell numbers after applying a gradual
increase in medium flow rate or a 5-day pre-culture period were
1.8-fold (p=0.0003) and 1.7-fold (p=0.0010) higher, respectively,
than in the high flow rate cultures.
Constructs from the low and gradually increasing flow rate
experiments contained 4.8-fold (p,0.0001) and 5.2-fold
(p,0.0001) higher GAG concentrations, respectively, compared
with those in the high flow rate cultures (Fig. 2a). GAG
concentrations in the 5-day pre-culture experiment were 3.0-fold
greater (p=0.005) than in the high flow rate cultures; however,
GAG concentrations in the 2.5-week pre-culture group were not
different statistically from those in the non-perfused and high flow
rate experiments. There was no significant difference in total
collagen concentration between any of the treatment groups
(Fig. 2b). Collagen type II concentrations were not significantly
different in constructs produced using the low flow rate, gradually
increasing flow rate, and 5-day pre-culture treatments: collagen
type II was not measured in the high flow rate and 2.5-week pre-
culture constructs (Fig. 2c). Collagen type II concentrations using
the gradually increasing flow rate and 5-day pre-culture treatments
were improved 7.8-fold (p=0.0032) and 7.0-fold (p=0.0064),
respectively, compared with the non-perfused controls. Results for
collagen type II as a percentage of total collagen were also
significantly higher using the low flow rate (p=0.0003), gradually
increasing flow rate (p,0.0001), and 5-day pre-culture (p=0.0016)
regimes relative to the non-perfused controls (Fig. 2d).
The histological appearance of constructs from the high flow
rate and gradually increasing flow rate cultures is shown in
Figure 3. The smaller size of the tissues produced under high flow
rate conditions (length 6.9 mm, maximum thickess 2.3 mm)
compared with those produced with gradually increasing flow
rate (length 14 mm, maximum thickess 3.5 mm) (Figs. 3a, 3b) is
consistent with visual observations of construct shrinkage in the
high flow rate experiments. Operating the bioreactor with
gradually increasing flow rate produced tissues with more intense
staining for GAG compared with those produced at high flow rate
(Figs. 3a, 3b), reflecting the quantitative results for GAG
Figure 1. Properties of cartilage constructs produced using
PGA scaffolds cultured in shaking T-flasks (non-perfused
control), in perfusion bioreactors using a constant flow rate
of 0.2 mL min
21 (high flow rate), a constant flow rate of
0.075 mL min
21 (low flow rate), or a gradually increasing flow
rate of 0.075–0.2 mL min
21 (gradual increase in flow rate), or
using scaffold pre-culture in T-flasks for either 5 days (5-day
pre-culture) or 2.5 weeks (2.5-week pre-culture) prior to
bioreactor culture at a constant flow rate of 0.2 mL min
21. (a)
Construct wet weight; and (b) number of cells. The scaffolds were
seeded using 20610
6 cells and cultured for a total of 5 weeks after
seeding. The error bars represent standard errors from triplicate T-flask
and/or bioreactor cultures. For each construct property, results labeled
with different letters (A, B, C) are statistically different from each other
(p,0.01).
doi:10.1371/journal.pone.0023119.g001
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stained positively for collagen type I (Figs. 3c, 3d); collagen type I
was localized mainly in the peripheral regions after the gradual
increase in flow rate treatment compared with a mostly internal
distribution in the high flow rate constructs. The development of
low GAG/high collagen type I capsules at the periphery of
cartilage constructs has been observed previously [15,16] and has
been attributed to high fluid shear, mixing, and turbulence at the
construct surface [2]. Immunostaining for collagen type II was
more intense and uniformly distributed in constructs produced
using a gradual increase in flow rate compared with high flow rate
conditions (Figs. 3e, 3f). Higher magnification of sections
immunostained for collagen type II (Figs. 3g, 3h) showed fewer
undissolved PGA fibers and cells of more rounded shape
surrounded by pericellular regions in constructs from the gradual
increase in flow rate cultures compared with those at high flow
rate. The presence of undissolved PGA fibers in the high flow rate
construct (seen in the lower half of Fig. 3g) is consistent with tissue
shrinkage and medium by-passing during the later stages of the
culture period.
Results for GAG release into the medium and retention in the
PGA constructs are shown in Figure 4. The cumulative amounts
of GAG released into the medium were higher for the low flow
rate, gradually increasing flow rate, and 5-day pre-culture
treatments compared with the high flow rate and 2.5-week pre-
culture groups (Fig. 4a). The average rates of GAG release into
the medium were 0.082, 0.24, 0.31, 0.25, and 0.064 mg day
21
for the high flow rate, low flow rate, gradually increasing flow
rate, 5-day pre-culture, and 2.5-week pre-culture groups,
respectively. Thus, the rate of GAG release correlated roughly
with the concentration of GAG in the tissues (Figs. 4a, 2a). As
the rate of GAG release can be expected to increase with
increasing GAG concentration in the constructs irrespective of
the medium flow or pre-culture conditions, calculation of the
overall specific rate of GAG release into the medium (mg per
day per mg of GAG in the constructs at harvest) provides a
more useful indicator of relative GAG retention between the
treatment groups. Results for the overall specific rate of GAG
release (Fig. 4b) highlight the superior relative levels of GAG
retention associated with the low flow rate, gradually increasing
flow rate, and 5-day pre-culture treatments. The total amount of
GAG (construct+medium) in the cultures at harvest was
determined and the percentage of total GAG retained within
the ECM calculated. The percentage of total GAG retained in
the tissues for the low and gradually increasing flow rate
treatments was 2.9–4.4-fold greater (p,0.0001) than in the high
flow rate and 2.5-week pre-culture groups (Fig. 4c). An
unreplicated measurement of medium GAG from the 5-day
pre-culture experiment yielded a 3.8–5.2-fold increase in
percentage GAG retention relative to the high flow rate and
2.5-week pre-culture groups but was not included in the
statistical analysis. In summary,a l t h o u g hg r e a t e ra m o u n t so f
GAG were lost to the medium during the low flow rate,
gradually increasing flow rate, and 5-day pre-culture experi-
ments (Fig. 4a), total GAG accumulation was also improved in
these cultures so that the proportion of total GAG lost into the
medium was only 43–56% compared with 89% using high flow
rate operation (Fig. 4c).
Figure 2. Biochemical properties of cartilage constructs
produced using PGA scaffolds cultured in shaking T-flasks
(non-perfused control), in perfusion bioreactors using a
constant flow rate of 0.2 mL min
21 (high flow rate), a constant
flow rate of 0.075 mL min
21 (low flow rate), or a gradually
increasing flow rate of 0.075–0.2 mL min
21 (gradual increase
in flow rate), or using scaffold pre-culture in T-flasks for either
5 days (5-day pre-culture) or 2.5 weeks (2.5-week pre-culture)
prior to bioreactor culture at a constant flow rate of
0.2 mL min
21. (a) GAG concentration; (b) total collagen concentra-
tion; (c) collagen type II concentration; and (d) collagen type II as a
percentage of total collagen. The scaffolds were seeded using 20610
6
cells and cultured for a total of 5 weeks after seeding. The error bars
represent standard errors from triplicate T-flask and/or bioreactor
cultures. n.a.=not analyzed. For each construct property, results labeled
with different letters (A, B, C, D) are statistically different from each other
(p,0.01).
doi:10.1371/journal.pone.0023119.g002
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The bioreactors in experiments with PGA–alginate scaffolds
were operated using a constant high flow rate of 0.2 mL min
21 or
a gradually increasing flow rate of 0.075–0.2 mL min
21. The
effect of pre-culturing the scaffolds in T-flasks for 5 days prior to
bioreactor culture at 0.2 mL min
21 was also tested. No shrinkage
of the PGA–alginate constructs was observed during these
experiments and there was negligible alginate residue (ca.
0.1 mg) in the tissues at harvest.
Results from analysis of constructs produced using PGA–
alginate scaffolds in Experiments 7–9 (Table 1) are shown in
Figures 5 and 6. There was no significant difference in tissue wet
weight, number of cells, GAG concentration, or total collagen
concentration between any of the groups tested (Figs. 5a, 5b, 6a,
6b). The water contents of the constructs were (94.560.4)%,
(92.060.3)%, and (89.860.3)% for the high flow rate, gradual
increase in flow rate, and 5-day pre-culture groups, respectively.
Collagen type II concentrations and levels of collagen type II as a
percentage of total collagen were 3.0-fold (p=0.0159) and 1.8-fold
(p=0.0208) greater, respectively, after the 5-day pre-culture
treatment than for the gradual increase in flow rate group
(Figs. 6c, 6d).
The histological appearance of PGA–alginate constructs from
the high flow rate and gradually increasing flow rate experiments
is shown in Figure 7. The staining intensity for GAG was similar in
the two cultures (Figs. 7a, 7b) consistent with the quantitative
Figure 3. Histological appearance of constructs produced using PGA scaffolds cultured in bioreactors for 5 weeks at a constant
flow rate of 0.2 mL min
21 (high flow rate: a, c, e, g) or gradually increasing flow rate of 0.075–0.2 mL min
21 (gradual increase in
flow rate: b, d, f, h). The scaffolds were seeded using 20610
6 cells. Construct cross-sections show: (a, b) pink–red staining for GAG; (c, d)
immunostaining (brown) for collagen type I; (e, f) immunostaining (brown) for collagen type II; and (g, h) immunostaining (brown) for collagen type II
and blue–purple staining for cells at high magnification.
doi:10.1371/journal.pone.0023119.g003
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at high flow rate produced tissues with a more pronounced
peripheral capsule of collagen type I compared with constructs
from the gradually increasing flow rate cultures (Figs. 7c, 7d). The
staining intensity for collagen type II was similar in the two
cultures (Figs. 7e, 7f) consistent with the quantitative results for
collagen type II concentration (Fig. 6c).
Results for GAG release into the medium and retention in the
constructs for the PGA–alginate scaffolds are shown in Figure 8.
Similar amounts of GAG were released during the three
treatments for most of the culture period (Fig. 8a); the average
rates of GAG release into the medium were 0.19, 0.28, and
0.22 mg day
21 for the high flow rate, gradually increasing flow
rate, and 5-day pre-culture treatments, respectively. There was no
significant difference in the overall specific rate of GAG release
into the medium (mg per day per mg of GAG in the constructs at
harvest) between the high and gradually increasing flow rate
treatments (Fig. 8b); the result using an unreplicated measurement
of medium GAG from the 5-day pre-culture treatment not
included in the statistical analysis is also shown in Figure 8b.
Figure 4. GAG release into the medium and retention in the
constructs for PGA scaffolds cultured in bioreactors operated
using a constant flow rate of 0.2 mL min
21 (high flow rate,N), a
constant flow rate of 0.075 mL min
21 (low flow rate, #), a
gradually increasing flow rate of 0.075–0.2 mL min
21 (gradual
increase in flow rate, %), or scaffold pre-culture in T-flasks for
either 5 days (5-day pre-culture, &) or 2.5 weeks (2.5-week pre-
culture, n) prior to bioreactor culture at a constant flow rate of
0.2 mL min
21. (a) Cumulative amount of GAG released into the
medium; (b) overall specific rate of GAG release (mg per day per mg of
GAG in the constructs at harvest); and (c) percentage of total GAG
(construct+medium) retained in the constructs. The scaffolds were
seeded using 20610
6 cells and cultured for a total of 5 weeks after
seeding. The error bars represent standard errors from triplicate
bioreactor cultures. Medium GAG data for the 5-day pre-culture
treatment were measured in only one of the triplicate bioreactors
and are thus unreplicated. In (b) and (c), results labeled with different
letters (A, B) are statistically different from each other (p,0.0001).
doi:10.1371/journal.pone.0023119.g004
Figure 5. Properties of cartilage constructs produced using
PGA–alginate scaffolds cultured in bioreactors using a con-
stant flow rate of 0.2 mL min
21 (high flow rate), a gradually
increasing flow rate of 0.075–0.2 mL min
21 (gradual increase
in flow rate), or scaffold pre-culture in T-flasks for 5 days prior
to bioreactor culture at a constant flow rate of 0.2 mL min
21
(5-day pre-culture). (a) Construct wet weight; and (b) number of cells.
The scaffolds were seeded using 20610
6 cells and cultured for a total of
5 weeks after seeding. The error bars represent standard errors from
triplicate bioreactors.
doi:10.1371/journal.pone.0023119.g005
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scaffolds (Fig. 8b) were roughly similar to those obtained for the
low flow rate, gradually increasing flow rate, and 5-day pre-culture
treatments using PGA scaffolds without alginate (Fig. 4b). In
contrast, results for the high flow rate cultures using PGA–alginate
(Fig. 8b) were about an order of magnitude lower than for the high
flow rate cultures without alginate (Fig. 4b). There was no
significant difference in the percentage of total GAG retained in
the tissues between the high and gradually increasing flow rate
groups using PGA–alginate; the unreplicated measurement from
the 5-day pre-culture experiment also gave a reasonably similar
result (Fig. 8c). GAG lost into the medium from the PGA–alginate
scaffolds accounted for 25–41% of total GAG in the cultures.
These results show that adding alginate to the scaffolds reduced
relative GAG losses compared with scaffolds without alginate even
under high flow rate conditions; however, in contrast to the
scaffolds without alginate, adjusting the medium flow rate or
applying pre-culture treatment produced no additional benefit for
the PGA–alginate cultures.
Proteoglycan integrity
Electrophoresis was used to investigate the size and integrity of
aggrecan molecules in the cartilage constructs and bioreactor
medium. As shown in Figure 9, all electrophoresed samples
produced smears rather than sharp bands, reflecting the
characteristic heterogeneity of proteoglycan composition and
glycosylation [32]. The migration fronts of the bands are used to
indicate the distance traveled by the samples. The three types of
aggrecan tested, bovine aggrecan, aggrecan isolated from human
fetal cartilage, and aggrecan isolated from tissue-engineered
cartilage, were separated on the gel (Fig. 9a, Lanes 3, 4). Aggrecan
from tissue-engineered cartilage (Fig. 9a, Lanes 6, 7) co-migrated
with aggrecan isolated from human fetal cartilage (Fig. 9a, Lane
5): the small difference in aggrecan size most likely reflects slightly
different post-translational modifications. All bands on the
Western blots (Figs. 9b, 9c) reacted with antibody against anti-
human aggrecan except chondroitin sulphate (Lane 2) and papain-
digested bovine aggrecan (Lane 9).
Most untreated proteoglycan in the spent culture medium
(Figs. 9a–9d, Lanes 8, 13) traveled only a very small distance on
the gel. Medium samples produced a smear with a distinct blue
color after toluidine blue staining (Fig. 9a), indicating the presence
of proteoglycans and GAG, and stained strongly with anti-
aggrecan antibody in the Western blot (Fig. 9c). Although some of
the medium sample co-migrated with aggrecan isolated from
tissue-engineered cartilage (Fig. 9b, Lanes 6–8), the large size of
the proteoglycan complexes in the medium suggested the presence
of aggregates that had not dissociated at the urea concentration
used to prepare the samples. Further addition of urea to a diluted
medium sample completely dissociated the aggregates (Fig. 9d,
Lane 12); digesting the sample with hyaluronidase resulted in
almost complete dissociation (Fig. 9d, Lane 14). With these
treatments, medium samples produced aggrecan bands that
traveled the same distance on the gel as aggrecan isolated from
tissue-engineered cartilage (Fig. 9d, Lane 11).
Figure 6. Biochemical properties of cartilage constructs
produced using PGA–alginate scaffolds cultured in bioreactors
using a constant flow rate of 0.2 mL min
21 (high flow rate), a
gradually increasing flow rate of 0.075–0.2 mL min
21 (gradual
increase in flow rate), or scaffold pre-culture in T-flasks for 5
days prior to bioreactor culture at a constant flow rate of
0.2 mL min
21 (5-day pre-culture). (a) GAG concentration; (b) total
collagen concentration; (c) collagen type II concentration; and (d)
collagen type II as a percentage of total collagen. The scaffolds were
seeded using 20610
6 cells and cultured for a total of 5 weeks after
seeding. The error bars represent standard errors from triplicate
bioreactors. Results labeled with different letters (A, B) are statistically
different from each other (p,0.05).
doi:10.1371/journal.pone.0023119.g006
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can molecules in the bioreactor medium was not significantly
different from those within the cartilage constructs. In addition,
medium proteoglycan was fully capable of aggregating and,
consequently, incorporating into the developing cartilage matrix.
As there was no evidence of proteoglycan degradation, loss of GAG
from the constructs into the medium is attributed to simple diffusion
or flushing out under the action of the perfusing medium rather
than to fragmentation due to proteolytic cleavage or turnover.
Discussion
Several strategies involving the manipulation of bioreactor
hydrodynamics, pre-culture conditions, scaffold design, and
seeding protocols were developed to reduce the loss of ECM
components from cartilage constructs during bioreactor culture.
For PGA scaffolds without alginate, applying a low or gradually
increasing flow rate during bioreactor culture, or pre-culturing the
scaffolds for 5 days prior to bioreactor culture, significantly
improved the size and quality of the constructs compared with the
non-perfused controls and bioreactor cultures operated at high
flow rate without scaffold pre-culture (Figs. 1, 2, 3). The relative
retention of GAG within the constructs was also improved
markedly using these treatments (Figs. 4b, 4c). Together, these
results suggest that moderated flow rates or scaffold pre-culture
under benign hydrodynamic conditions protected early-formed
ECM from being flushed away, allowing it to form a framework
within the scaffold on to which other synthesized elements could
Figure 7. Histological appearance of constructs produced using PGA–alginate scaffolds cultured in bioreactors for 5 weeks at a
constant high flow rate of 0.2 mL min
21 (a, c, e) or a gradually increasing flow rate of 0.075–0.2 mL min
21 (b, d, f). The scaffolds
were seeded using 20610
6 cells. Construct cross-sections show: (a, b) pink–red staining for GAG, blue staining for collagen, and dark blue–purple
staining for cells; (c, d) immunostaining (brown) for collagen type I; and (e, f) immunostaining (brown) for collagen type II.
doi:10.1371/journal.pone.0023119.g007
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the bioreactors. This finding is consistent with previous reports of
reduced GAG accumulation in cultures perfused during the early
stages of cartilage synthesis [10,33] and with increasing medium
flow rate [34], indicating that the beneficial effects of perfusion
depend on first allowing deposition of some matrix around the
cells as well as judicious control of the flow forces applied. In the
current study, the relatively poor results using 2.5 weeks of pre-
culture in T-flasks (Figs. 1a, 2a, 4) suggest that, whereas protection
of the cells and developing matrix for several days before
bioreactor culture was beneficial, 2.5 weeks was too long a period
for the cells to maintain strong chondrogenic activity without the
benefits of nutrient perfusion and hydrodynamic stimulation.
In contrast to the results with PGA scaffolds, the gradually
increasing flow rate and 5-day pre-culture treatments had
relatively little effect on construct quality and GAG retention in
PGA–alginate scaffolds compared with cultures conducted at high
medium flow rate (Figs. 5, 6, 7, 8). Yet, in many respects, the
PGA–alginate scaffolds produced constructs with wet weights,
biochemical composition, and GAG retention characteristics
similar to or better than the maximum results obtained using
PGA scaffolds without alginate (Figs. 5, 6, 7, 8 cf Figs. 1, 2, 3, 4).
This suggests that the presence of alginate between the fibers of the
scaffold protected the cells and developing matrix even at the
highest flow rate tested and without scaffold pre-culture. The
average pore size in alginate gel has been measured as
0.3760.03 mm [35], which is much smaller than the pore
dimensions of several hundred microns in fibrous PGA mesh
[36–38]. As monomeric aggrecans extend to about 300 nm [39]
and collagen fibers measure approximately 50 mm6240 nm [40],
filling the interstices of PGA scaffolds with alginate can be
expected to reduce strongly the release of these elements into the
culture medium. This is consistent with overall specific rates of
GAG release being an order-of-magnitude lower in the high flow
rate cultures with PGA–alginate scaffolds compared with the high
flow rate cultures and PGA alone (Figs. 4b, 8b).
Theoretically, the rate of transport of any component from the
cartilage constructs into the medium depends on the porosity and
other retentive properties of the scaffold and ECM, the magnitude
of the shear forces acting on the construct, the surface area
available for transfer, and the difference in component concen-
tration between the tissue and medium. Consistent with the last
factor in this list, the cumulative amounts of GAG released were
generally higher in the better performing cultures that contained
relatively high concentrations of GAG in the tissues (Figs. 2a, 4a,
6a, 8a). As well as GAG, collagen or procollagen may also have
been released from the constructs. However, because hydroxy-
proline was present at relatively high concentration in the culture
medium used, it was not possible to measure collagen release using
analytical methods based on hydroxyproline. Concentrations of
hydroxyproline in fresh culture medium and in samples of spent
medium (n=3) were found to be 360611 mgm L
21 and
2062.0 mgm L
21, respectively. It was thus difficult to distinguish
between residual hydroxyproline provided in the medium and
collagen or procollagen that may have been released from the
developing tissues. The ELISA used for measurement of collagen
type II was not applied to medium samples because of the high
cost of analyzing the large number of samples generated by routine
medium exchange. Although stripping of collagen from the PGA
constructs remains a possibility, in contrast to the results found for
GAG, there was no significant improvement in total collagen
content compared with the non-perfused and high flow rate
cultures when the low flow rate, gradually increasing flow rate, and
5-day pre-culture treatments were applied (Fig. 2b).
Figure 8. GAG release into the medium and retention in the
constructs for PGA–alginate scaffolds cultured in bioreactors
operated using a constant flow rate of 0.2 mL min
21 (high flow
rate,N), a gradually increasing flow rate of 0.075–0.2 mL min
21
(gradual increase in flow rate, %), or scaffold pre-culture in T-
flasks for 5 days prior to bioreactor culture at a constant flow
rate of 0.2 mL min
21 (5-day pre-culture, &). (a) Cumulative
amount of GAG released into the medium; (b) overall specific rate of
GAG release (mg per day per mg of GAG in the constructs at harvest);
and (c) percentage of total GAG (construct+medium) retained in the
constructs. The scaffolds were seeded using 20610
6 cells and cultured
for a total of 5 weeks after seeding. The error bars represent standard
errors from triplicate bioreactors. Medium GAG data for the 5-day pre-
culture treatment were measured in only one of the triplicate
bioreactors and are thus unreplicated.
doi:10.1371/journal.pone.0023119.g008
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PLoS ONE | www.plosone.org 10 August 2011 | Volume 6 | Issue 8 | e23119Figure 9. Analysis of proteoglycan size and integrity: (a and d) results from electrophoresis on composite acrylamide–agarose gels;
(b and c) results from Western blots probed using monoclonal antibody specific to the hyaluronic-acid-binding region of human
aggrecan. The back-up nitrocellulose membrane for capture of smaller-sized molecules is shown in (b); the primary membrane showing larger-sized
molecules is shown in (c). Lane 1 – aggrecan from bovine cartilage; Lane 2 – chondroitin sulphate from shark cartilage; Lane 3 – a 1:1 w/w mixture of
bovine aggrecan and chondroitin sulphate; Lane 4 – a 1:1 w/w mixture of bovine aggrecan and proteoglycans isolated from human fetal cartilage;
Lane 5 – proteoglycans isolated from human fetal cartilage; Lanes 6 and 7 –proteoglycans isolated from tissue-engineered cartilage; Lane 8 – spent
medium from bioreactor culture of tissue-engineered cartilage; Lane 9 – bovine aggrecan digested with papain; Lane 10 – aggrecan from bovine
cartilage; Lane 11 – proteoglycans isolated from human fetal cartilage; Lanes 12, 13 and 14 – spent medium from bioreactor culture of tissue-
engineered cartilage. The sample in Lane 12 was diluted and treated with 6 M urea; the sample in Lane 14 was treated with hyaluronidase.
doi:10.1371/journal.pone.0023119.g009
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alginate during the non-perfused control, high flow rate, and 2.5-
week pre-culture experiments. Articular chondrocytes are known
to express a-smooth muscle actin, a contractile actin isoform, and
this has been related to the ability of chondrocytes to contract
polymeric scaffolds during cartilage formation [41]. Scaffold
contraction is generally undesirable because it alters the pore
structure and shape of the scaffold; remedial strategies such as
constraining scaffolds by clamping [42] or using highly cross-
linked scaffold materials [43] have been employed. In the current
work, contraction of PGA scaffolds under two of the bioreactor
culture conditions tested resulted in some degree of medium by-
passing with fluid flowing between the tissue and bioreactor wall.
Nutrient and oxygen deprivation may have occurred in the
constructs under these conditions, contributing to the poor tissue
development and low GAG concentrations observed in the high
flow rate and 2.5-week pre-culture experiments (Figs. 1a, 2a). The
relatively high content of undissolved PGA fibers in the high flow
rate constructs (Fig. 3g) is also consistent with medium by-passing.
Proteolysis of cartilage proteoglycan occurs continuously in the
body throughout life; accelerated degradation of proteoglycans is a
characteristic of diseases such as arthritis that damage the normal
structure and function of cartilage [25]. The loss of GAG from
cartilage constructs into the medium during bioreactor culture
raises the question of whether these losses are due to simple
flushing out of full-size molecules from immature and relatively
porous tissues as a result of medium perfusion, or whether
proteoglycans within the constructs are proteolytically degraded
into smaller fragments, thus facilitating their removal. The
integrity of proteoglycan aggrecan in the tissue-engineered
constructs and medium was investigated using electrophoresis.
Acrylamide–agarose gels were successful in separating very large
and small proteoglycan and GAG molecules on the same gel
without the need for sample purification or enzyme treatment of
samples as required using SDS–PAGE [44,45]. The results
showed no evidence of proteoglycan degradation: after dissocia-
tion, aggrecan complexes in the bioreactor medium were similar in
size to those in native human cartilage and within the tissue-
engineered constructs (Fig. 9). Accordingly, loss of GAG from
cultured tissues into the medium is attributed to simple removal of
intact proteoglycan rather than to proteolytic cleavage or
turnover.
Substantial improvements in GAG concentration, collagen type
II concentration, and levels of collagen type II as a percentage of
total collagen were obtained in this work by modifying the
structure and composition of the scaffold and the conditions used
for perfusion culture in bioreactors. The results demonstrate a
direct link between cartilage construct quality and relative GAG
retention. The first few days of culture were found to be critical for
the proper formation of de novo tissue-engineered cartilage. Low
flow rates are needed with porous scaffolds such as PGA only
during the first week or so to protect early-deposited ECM until a
macromolecular framework is developed to capture other
synthesized elements. This was also achieved using a relatively
short (5-day) pre-culture period before bioreactor operation. The
presence of alginate gel within fibrous PGA scaffolds reduced the
loss of ECM components from the constructs and obviated the
need for flow rate modulation or scaffold pre-culture to protect the
developing matrix.
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